Targeting the hepatic adropin signaling pathway in obesity
Targeting the hepatic adropin signaling pathway in obesity
批准号:
10677279
负责人:
Bellina Mushala
金额:
$4.32万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-04-01 至 2024-01-31
关键词:
AddressAnimal ModelApoptosisAtherosclerosisBiochemicalBioenergeticsBiological ProcessBrainCardiacCell membraneCellsComplexCoronary ArteriosclerosisDefectDevelopmentDiabetes MellitusDietDiseaseDisease ProgressionEducationEndotheliumEnergy Metabolism PathwayEnzymesEssential GenesExhibitsFatty AcidsFatty LiverFatty acid glycerol estersFellowshipFibrosisG-Protein-Coupled ReceptorsGenetic DiseasesGlucoseGoalsHeartHepaticHepatocyteHistologicHomeostasisImmunohistochemistryImpairmentIn VitroInflammationInflammatory ResponseKnock-outKnockout MiceLigandsLinkLipidsLiverMeasuresMediatingMediatorMetabolicMetabolic DiseasesMetabolismMolecularNull LymphocytesNutrientNutrition DisordersObesityObesity associated diseaseObesity associated liver diseaseOrphanPPAR gammaPathologicPathologyPeripheralPhenotypePopulationPrevalenceRecombinantsRegulationRegulatory PathwayResearchResistanceRisk FactorsRoleSignal PathwaySignal TransductionTechniquesTestingTherapeutic EffectTissuesTrainingUnited StatesUp-RegulationWestern BlottingWild Type Mouseblood glucose regulationcareerdesigndiabeticeffective therapyhuman subjectin vivolipid metabolismliver developmentliver injurymouse modelnon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnoveloxidationoxidative damagepeptide hormonepreventable deathprotective effectreceptorresponseuptake
中文摘要
项目概要/摘要
肥胖是美国可预防死亡的第二大原因。肥胖是一种复杂的营养
以及由能量失衡引起的遗传性疾病,并成为各种疾病的基本风险因素
病理包括冠状动脉疾病、糖尿病、非酒精性脂肪肝和动脉粥样硬化。
在不同组织中驱动肥胖相关疾病的细胞和分子机制尚不完全清楚
已阐明,这对开发有效且高效的治疗方法构成了障碍。阿德罗平
是一种最近鉴定的肝源性和脑源性肽激素,对燃料产生强大的影响
外周组织的底物代谢。肥胖和糖尿病患者的 Adropin 水平显着降低
人类受试者,这种减少与肥胖增加和葡萄糖稳态受损有关。
此外,adropin 消耗与肝脏相关肥胖疾病的发展有关
例如 NAFLD 和 NASH。在本次奖学金申请中,我们将确定分子信号传导途径
adropin 在肝脏燃料代谢中的潜在功能,并研究其对 NAFLD 和
纳什。在目标 1 中,我们将确定 adropin 如何与细胞膜受体 GPR19 结合来调节
肝细胞燃料代谢。在目标 2 中,我们将确定 GPR19 是否对于以下物质的保护作用是必要的:
adropin 抗肝损伤。通过结合尖端的代谢技术和全面的训练
计划,这项奖学金将使我为代谢研究和科学职业生涯的下一阶段做好准备
教育。
英文摘要
PROJECT SUMMARY/ABSTRACT
Obesity is the second leading cause of preventable death in the United States. Obesity is a complex nutritional
and genetic disorder that is driven by energy imbalances, and serves as a fundamental risk factor in various
pathologies including coronary artery disease, diabetes, non-alcoholic fatty liver disease, and atherosclerosis.
The cellular and molecular mechanisms that drive obesity-related disease in different tissues are not fully
elucidated, and this represents an impediment to the development of effective and efficient treatments. Adropin
is a recently characterized liver- and brain-derived peptide hormone that exerts powerful effects on fuel
substrate metabolism in peripheral tissues. Adropin levels are significantly reduced in obese and diabetic
human subjects, and this decrease is linked to increased adiposity and impaired glucose homeostasis.
Furthermore, adropin depletion has been linked with the development of liver-associated obesity diseases
such as NAFLD and NASH. In this fellowship application, we will determine the molecular signaling pathways
underlying adropin function in liver fuel metabolism, and investigate its protective effects against NAFLD and
NASH. In Aim 1, we will determine how adropin associates with the cell membrane receptor GPR19 to regulate
hepatocyte fuel metabolism. In Aim 2, we will determine if GPR19 is necessary for the protective effects of
adropin against hepatic injury. By combining cutting-edge metabolic techniques and a comprehensive training
plan, this fellowship will allow me to prepare for the next stage of my career in metabolic research and scientific
education.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金